Gain Therapeutics' newly-appointed CEO Matthias Alder offers up a deep, yet abundantly clear explanation of how his company is applying compute power to speed up  drug discovery.  At Gain, computational models help researchers winnow down not just which molecules might have therapeutic effect, but also how adept those molecules will be at binding--and staying bound--to their target. It's not just theory, either. On this episode of the Business of Biotech, Alder shares on how the virtual successes seen on Gain's servers have translated in the wet lab, and how they've contributed to the company's fast-growing preclinical pipeline. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!